Literature DB >> 16972185

Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation.

Handoko Adi1, Ian Larson, Herbert Chiou, Paul Young, Daniela Traini, Peter Stewart.   

Abstract

PURPOSE: The study investigated the role of agglomeration and the effect of fine lactose size on the dispersion of salmeterol xinafoate (SX) from SX-lactose mixtures for inhalation.
METHODS: Particle size distributions were characterised by Malvern Mastersizer S, Aerosizer and Spraytec, and imaging conducted by scanning electron microscopy (SEM). Inter-particulate adhesion was quantified by atomic force microscopy. Deposition of SX was measured using a twin stage impinger. SX was analysed using validated high-performance liquid chromatography method (r(2)=1.0, CV=0.4-1.0%).
RESULTS: Addition of fine lactose with a volume median diameter (VMD) of 7.9 microm to a SX-lactose carrier and carrier-free mixture resulted in significantly better dispersion (16.8% for 20% added fine lactose) than fractions with VMD of 3.0, 17.7 and 33.3 microm (less than 9.1% for 20% fine lactose). Using the carrier-free mixtures, particle sizing of the aerosol cloud using the Spraytec, coupled with the application of the Aerosizer using differing dispersion energies and SEMs of the samples, indicated that an open packed, agglomerate structure improved SX dispersion. The highest extent of SX dispersion occurred when SX and fine lactose were detached from the surface, usually in the form of loose agglomerates.
CONCLUSIONS: The outcomes of this research demonstrated how agglomerate structure influenced dispersion and the key role of fine lactose particle size in SX dispersion from mixtures for inhalation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972185     DOI: 10.1007/s11095-006-9082-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures.

Authors:  Margaret D Louey; Sultana Razia; Peter J Stewart
Journal:  Int J Pharm       Date:  2003-02-18       Impact factor: 5.875

2.  The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.

Authors:  X M Zeng; K H Pandhal; G P Martin
Journal:  Int J Pharm       Date:  2000-03-20       Impact factor: 5.875

3.  Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.

Authors:  P Lucas; K Anderson; J N Staniforth
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  Particle interactions involved in aerosol dispersion of ternary interactive mixtures.

Authors:  Margaret D Louey; Peter J Stewart
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

5.  Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?

Authors:  Nazrul Islam; Peter Stewart; Ian Larson; Patrick Hartley
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

6.  Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.

Authors:  Nazrul Islam; Peter Stewart; Ian Larson; Patrick Hartley
Journal:  J Pharm Sci       Date:  2004-04       Impact factor: 3.534

  6 in total
  10 in total

1.  Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.

Authors:  V N P Le; T H Hoang Thi; E Robins; M P Flament
Journal:  AAPS PharmSciTech       Date:  2012-03-08       Impact factor: 3.246

2.  Powder strength distributions for understanding de-agglomeration of lactose powders.

Authors:  Shyamal C Das; Srinivas Ravindra Babu Behara; Jurgen B Bulitta; David A V Morton; Ian Larson; Peter J Stewart
Journal:  Pharm Res       Date:  2012-06-14       Impact factor: 4.200

3.  An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.

Authors:  Matthew D Jones; Jennifer C Hooton; Michelle L Dawson; Alan R Ferrie; Robert Price
Journal:  Pharm Res       Date:  2007-10-19       Impact factor: 4.200

4.  Characterizations of particle size distribution of the droplets exhaled by sneeze.

Authors:  Z Y Han; W G Weng; Q Y Huang
Journal:  J R Soc Interface       Date:  2013-09-11       Impact factor: 4.118

5.  An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.

Authors:  Hanne Kinnunen; Gerald Hebbink; Harry Peters; Jagdeep Shur; Robert Price
Journal:  AAPS PharmSciTech       Date:  2014-04-23       Impact factor: 3.246

6.  Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.

Authors:  Hiroko Otake; Tomoyuki Okuda; Daiki Hira; Haruyoshi Kojima; Yasuhiro Shimada; Hirozazu Okamoto
Journal:  Pharm Res       Date:  2015-12-07       Impact factor: 4.200

7.  Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction.

Authors:  Sara Jaffari; Ben Forbes; Elizabeth Collins; David J Barlow; Gary P Martin; Darragh Murnane
Journal:  Int J Pharm       Date:  2013-02-19       Impact factor: 5.875

8.  New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.

Authors:  Floris Grasmeijer; Anne J Lexmond; Maarten van den Noort; Paul Hagedoorn; Anthony J Hickey; Henderik W Frijlink; Anne H de Boer
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

9.  Effect of Lactose Pseudopolymorphic Transition on the Aerosolization Performance of Drug/Carrier Mixtures.

Authors:  Andrea Della Bella; Michele Müller; Andrea Danani; Luciano Soldati; Ruggero Bettini
Journal:  Pharmaceutics       Date:  2019-11-04       Impact factor: 6.321

10.  Physicochemical characteristics and bronchial epithelial cell cytotoxicity of Folpan 80 WG(R) and Myco 500(R), two commercial forms of folpet.

Authors:  Mireille Canal-Raffin; Beatrice L'azou; Beatrice Martinez; Elisabeth Sellier; Fawaz Fawaz; Philip Robinson; Celine Ohayon-Courtès; Isabelle Baldi; Jean Cambar; Mathieu Molimard; Nicholas Moore; Patrick Brochard
Journal:  Part Fibre Toxicol       Date:  2007-09-20       Impact factor: 9.400

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.